Table 3.

Clinical and Treatment Details of Patients With Common Terminology Criteria for Adverse Events Version 5.0 Grade 2 or Higher Treatment-Related Pneumonitis

Patient	Pneumonitis grade	Age/Sex	Osimertinib delivery	Tumor location	Prescription	MLD (Gy)	V5	V20	Pulmonary comorbidity	Smoking history	Concurrent chemotherapy	Time to Pneumonitis (mo)
1	5	70/F	Held for RT	Peripheral lung	6 Gy ×5	2.8	9.2	2.8	None	Former (20PY)	No	3.2
2	5	95/F	Held for RT	Central	8 Gy ×5	4.75	25.3	4.0	None	Never smoker	No	4.4
3	3	62/F	Held for RT	Ultracentral	4 Gy ×13	11.2	44.8	17.7	None	Never smoker	No	5.4
4	3	49/F	Held for RT	Ultracentral	2.5 Gy ×12	2.7	12.5	4.8	Prior radiation to the same lung lesion	Never smoker	Yes	4.5
5	3	72/F	Overlapping with RT	Thoracic spine	3 Gy ×10	3.73	19.7	4.7	Prior pneumonectomy	Former (20PY)	No	1.6
6	2	66/F	Held for RT	Ultracentral	2 Gy ×30	18	59.1	29.7	None	Never smoker	Yes	2.1
7	2	53/F	Held for RT	Ultracentral	7.5 Gy ×8	6.8	24.1	10.3	Asthma	Former (25PY)	No	6.3
8	2	74/F	Held for RT	Ultracentral	7.5 Gy ×8	5.3	18.5	8.9	COPD, lobectomy + wedge resection	Former (45PY)	No	3.5
9	2	51/F	Held for RT	Peripheral	18 Gy ×3	1.9	7.0	2.5	None	Never smoker	No	5.3
10	2	72/F	Held for RT	Ultracentral	2 Gy ×33	14.3	43.3	23.6	None	Former (20PY)	Yes	3.1
11	2	46/F	Held for RT	Ultracentral	2 Gy ×33	17.6	63.6	33.0	None	Never smoker	Yes	1.5
12	2	68/F	Overlapping with RT	Central	12 Gy ×5	6	32.3	7.2	Prior pulmonary embolism	Former (45PY)	No	2.7
13	2	63/M	Held for RT	Ultracentral	3 Gy ×10	Unavailable			None	Never smoker	No	2.1
14	2	73/F	Held for RT	Ultracentral	8 Gy ×2	3.01	16.3	0.0	None	Never smoker	No	2.6

F, female; M, male; MLD, mean lung dose; PY, pack-years; RT, radiotherapy; V5, lung volume receiving a dose of ≥5 Gy; V20, lung volume receiving a dose of ≥20 Gy.